Xavier Cathelineau
Research Subjects
Xavier Cathelineau has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Marc Galiano
Clinique de l'Alma, Urology , Paris , France
18 shared publications F. Rozet
16 shared publicationsE. Barret
9 shared publicationsD. Prapotnich
7 shared publications- Eliza Barret
Department of Pharmacy, Bichat University Hospital, Paris, France
7 shared publications - Rafael Sanchez-Salas
Department of Urology, Institut Mutualiste Montsouris, Paris, France
7 shared publications
Latest Publications
- 30 October 2022
- Published by Elsevier in EMC - Urología
- Vol. 54 (4) , 1-6
Técnicas, indicaciones y resultados del vaciamiento ganglionar por vía laparoscópica robótica en el tratamiento del cáncer de próstata
- 30 October 2022
- Published by Elsevier in EMC - Urología
- Vol. 54 (4) , 1-6
Técnicas, indicaciones y resultados del vaciamiento ganglionar por vía laparoscópica robótica en el tratamiento del cáncer de próstata
- 1 June 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (3) , 199-209
The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance
- 1 June 2022
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (3) , 199-209
The Cancer of the Bladder Risk Assessment (COBRA) score accurately predicts cancer-specific survival after radical cystectomy: external validation and lymphovascular invasion assessment value to improve its performance
- 1 February 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (2) , 139-145
Cure de fistule recto-urétrale par la technique modifiée de York Mason : évaluation des facteurs d’échec
- 1 February 2022
- Published by Elsevier in Progrès en Urologie
- Vol. 32 (2) , 139-145
Cure de fistule recto-urétrale par la technique modifiée de York Mason : évaluation des facteurs d’échec
- 8 October 2021
- Published by Springer Nature in Current Urology Reports
- Vol. 22 (10) , 1-10
Robotic-Assisted Partial Nephrectomy: Techniques to Improve Clinical Outcomes
Purpose of Review To summarize current options available for robot-assisted partial nephrectomy Recent Findings Partial nephrectomy (PN) is a standard treatment option for management of cT1 renal masses. It may be carried out by multiple approaches. Robot-assisted (RA) PN is one such option. The goal of treatment is both correct oncological (negative surgical margins) and functional (preservation of sufficient amount of renal parenchyma of the operated kidney) outcome. Appropriate outcomes depend on multiple factors. There are many, but among others tumor characteristics (size, location, i.e., tumor complexity), patient baseline renal function, patient comorbidities, and performance status etc. Based on all these, the surgeon adapts the intervention for each mass/patient by preoperative planning, absence/use/duration of warm or cold ischemia, perioperative imaging, resection technique adapted to tumor location and depth of invasion, use of hemostatics, type and degree of renal parenchymal closure and others details. Nephroprotective agents have not shown efficacy so far. It should not be forgotten that surgeon’s experience plays a key role in the achievement of good results. Summary Although multiple factors have a role in the RA partial nephrectomy, surgeon experience and adaptation of technique of intervention have the crucial role in the achievement of both functional and oncological results.
- 8 October 2021
- Published by Springer Nature in Current Urology Reports
- Vol. 22 (10) , 1-10
Robotic-Assisted Partial Nephrectomy: Techniques to Improve Clinical Outcomes
Purpose of Review To summarize current options available for robot-assisted partial nephrectomy Recent Findings Partial nephrectomy (PN) is a standard treatment option for management of cT1 renal masses. It may be carried out by multiple approaches. Robot-assisted (RA) PN is one such option. The goal of treatment is both correct oncological (negative surgical margins) and functional (preservation of sufficient amount of renal parenchyma of the operated kidney) outcome. Appropriate outcomes depend on multiple factors. There are many, but among others tumor characteristics (size, location, i.e., tumor complexity), patient baseline renal function, patient comorbidities, and performance status etc. Based on all these, the surgeon adapts the intervention for each mass/patient by preoperative planning, absence/use/duration of warm or cold ischemia, perioperative imaging, resection technique adapted to tumor location and depth of invasion, use of hemostatics, type and degree of renal parenchymal closure and others details. Nephroprotective agents have not shown efficacy so far. It should not be forgotten that surgeon’s experience plays a key role in the achievement of good results. Summary Although multiple factors have a role in the RA partial nephrectomy, surgeon experience and adaptation of technique of intervention have the crucial role in the achievement of both functional and oncological results.
- 1 February 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (1) , 3-11.e1
Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis
- 1 February 2021
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (1) , 3-11.e1
Accuracy of MRI-guided Versus Systematic Prostate Biopsy in Patients Under Active Surveillance: A Systematic Review and Meta-analysis
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (1) , S49-S55
Ablative options for prostate cancer management
This review provides an overview of the available ablative options for prostate cancer (PCa) management. It contemplates the ablative concepts and the role of prostate ablation in different settings, from primary treatment to repeat ablation, and as an alternative to radiorecurrent disease. Improvements in prostate imaging have allowed us to ablate prostate lesions through thermal, mechanical, and vascular-targeted sources of energy. Partial gland ablation (PGA) has an emerging role in the management of localized PCa because toxicity outcomes have been proven less harmful compared with whole-gland treatments. Although long-term oncological outcomes are yet to be consolidated in comparative studies, recent large series and prospective studies in PGA have reported encouraging results. A second ablation after disease recurrence has demonstrated low toxicity, and future studies must define its potential to avoid radical treatments. PGA is an attractive option for PCa management in different scenarios because of its low-toxicity profile. As expected, recurrence rates are higher than those seen in whole-gland procedures. Long-term oncological outcomes of primary and salvage options are required to endorse it among the standard treatments. Cite this article as: Tourinho-Barbosa RR, Batista LT, Cathelineau X, Sanchez-Macias J, Sanchez-Salas R. Ablative options for prostate cancer management. Turk J Urol 2020; 47(Supp. 1): S49-S55.
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (1) , S49-S55
Ablative options for prostate cancer management
This review provides an overview of the available ablative options for prostate cancer (PCa) management. It contemplates the ablative concepts and the role of prostate ablation in different settings, from primary treatment to repeat ablation, and as an alternative to radiorecurrent disease. Improvements in prostate imaging have allowed us to ablate prostate lesions through thermal, mechanical, and vascular-targeted sources of energy. Partial gland ablation (PGA) has an emerging role in the management of localized PCa because toxicity outcomes have been proven less harmful compared with whole-gland treatments. Although long-term oncological outcomes are yet to be consolidated in comparative studies, recent large series and prospective studies in PGA have reported encouraging results. A second ablation after disease recurrence has demonstrated low toxicity, and future studies must define its potential to avoid radical treatments. PGA is an attractive option for PCa management in different scenarios because of its low-toxicity profile. As expected, recurrence rates are higher than those seen in whole-gland procedures. Long-term oncological outcomes of primary and salvage options are required to endorse it among the standard treatments. Cite this article as: Tourinho-Barbosa RR, Batista LT, Cathelineau X, Sanchez-Macias J, Sanchez-Salas R. Ablative options for prostate cancer management. Turk J Urol 2020; 47(Supp. 1): S49-S55.
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD34-06 COMPREHENSIVE EVALUATION OF COMPLICATIONS OF FOCAL THERAPY: A STANDARDIZED METHODOLOGY
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
Open AccessPD34-06 COMPREHENSIVE EVALUATION OF COMPLICATIONS OF FOCAL THERAPY: A STANDARDIZED METHODOLOGY
- Open Access
- 1 October 2017
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 43 (5) , 995-996
Focal cryotherapy: step by step technique description
Focal cryotherapy emerged as an efficient option to treat favorable and localized prostate cancer (PCa). The purpose of this video is to describe the procedure step by step. We present the case of a 68 year-old man with localized PCa in the anterior aspect of the prostate. The procedure is performed under general anesthesia, with the patient in lithotomy position. Briefly, the equipament utilized includes the cryotherapy console coupled with an ultrasound system, argon and helium gas bottles, cryoprobes, temperature probes and an urethral warming catheter. The procedure starts with a real-time trans-rectal prostate ultrasound, which is used to outline the prostate, the urethra and the rectal wall. The cryoprobes are pretested and placed in to the prostate through the perineum, following a grid template, along with the temperature sensors under ultrasound guidance. A cystoscopy confirms the right positioning of the needles and the urethral warming catheter is installed. Thereafter, the freeze sequence with argon gas is started, achieving extremely low temperatures (-40ºC) to induce tumor cell lysis. Sequentially, the thawing cycle is performed using helium gas. This process is repeated one time. Results among several series showed a biochemical disease-free survival between 71-93% at 9-70 month- follow-up, incontinence rates between 0-3.6% and erectile dysfunction between 0-42% (1-5). Focal cryotherapy is a feasible procedure to treat anterior PCa that may offer minimal morbidity, allowing good cancer control and better functional outcomes when compared to whole-gland treatment.
- 1 October 2017
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 43 (5) , 995-996
Open AccessFocal cryotherapy: step by step technique description
Focal cryotherapy emerged as an efficient option to treat favorable and localized prostate cancer (PCa). The purpose of this video is to describe the procedure step by step. We present the case of a 68 year-old man with localized PCa in the anterior aspect of the prostate. The procedure is performed under general anesthesia, with the patient in lithotomy position. Briefly, the equipament utilized includes the cryotherapy console coupled with an ultrasound system, argon and helium gas bottles, cryoprobes, temperature probes and an urethral warming catheter. The procedure starts with a real-time trans-rectal prostate ultrasound, which is used to outline the prostate, the urethra and the rectal wall. The cryoprobes are pretested and placed in to the prostate through the perineum, following a grid template, along with the temperature sensors under ultrasound guidance. A cystoscopy confirms the right positioning of the needles and the urethral warming catheter is installed. Thereafter, the freeze sequence with argon gas is started, achieving extremely low temperatures (-40ºC) to induce tumor cell lysis. Sequentially, the thawing cycle is performed using helium gas. This process is repeated one time. Results among several series showed a biochemical disease-free survival between 71-93% at 9-70 month- follow-up, incontinence rates between 0-3.6% and erectile dysfunction between 0-42% (1-5). Focal cryotherapy is a feasible procedure to treat anterior PCa that may offer minimal morbidity, allowing good cancer control and better functional outcomes when compared to whole-gland treatment.
- 25 September 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (6) , e2269
Salvage Robotic-assisted Radical Prostatectomy: Oncologic and functional outcomes from two high-volume institutions
- 25 September 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (6) , e2269
Salvage Robotic-assisted Radical Prostatectomy: Oncologic and functional outcomes from two high-volume institutions